Investment Strategies

     MANHATTAN – An endocrinologist is still awaiting share certificates after investing half a million dollars in Medolife based on its Escozine cancer treatment, derived from the venom of blue scorpions, and its “polarization technology,” she claims in a federal complaint.

%d bloggers like this: